Assessing the Predictive Role of Platelet-lymphocyte Ratio in EGFR-mutated Non-small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: an Analysis Across TKI Generations

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Nov 21

PMID 39570469

Authors

Ryan Cooper

Dhruv Ramaswami

Jacob S Thomas

Jorge J Nieva

Robert Hsu

Affiliations

Soon will be listed here.

Abstract

Introduction: The predictive utility of laboratory markers in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations treated with tyrosine kinase inhibitors (TKIs) is an ongoing area of research. The predictability of the platelet-lymphocyte ratio (PLR) on survival outcomes depending on the generation of EGFR TKI is undetermined.

Methods: 151 patients treated with EGFR TKIs in Los Angeles were grouped according to generation of TKI. Differences in progression free survival (PFS) by stratification by PLR was determined using Kaplan-Meier analysis. Differences in median change in laboratory markers by generation of TKI was analyzed using Mann-Whitney tests. Cox Hazard Regression was used to perform multivariate analysis.

Results: Median PFS of those managed with 1st or 2nd generation TKIs was significantly lower in patients with a PLR ≥ 180 (10.5 months) compared to those with PLR < 180 (16.6 months, p = 0.0163). Median PFS was comparable in those treated with osimertinib regardless of PLR. Patients managed with osimertinib had a significant decrease in absolute lymphocyte count (ALC) at 6 weeks and in platelets at 6 weeks and 3 months compared to those managed with 1st or 2nd generation TKIs.

Discussion: The predictive value of PLR was more apparent in patients treated with 1st or 2nd generation TKIs compared to those treated with osimertinib. Third generation EGFR TKIs may be more efficacious in treating patients with laboratory findings previously shown to predict poor survival. The significant changes in peripheral cell counts suggest variable tumor microenvironment changes dependent on the generation of TKI received.

References

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Barker T, Fulde G, Moulton B, Nadauld L, Rhodes T . An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer. Sci Rep. 2020; 10(1):7535. PMC: 7200806. DOI: 10.1038/s41598-020-64282-z. View

Zhou Q, Dong J, Sun Q, Lu N, Pan Y, Han X . Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis. BMJ Open. 2021; 11(9):e047957. PMC: 8475153. DOI: 10.1136/bmjopen-2020-047957. View

Sim S, Beom S, Ahn Y, Keam B, Kim T, Lee S . Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors. Thorac Cancer. 2016; 7(2):161-6. PMC: 4773306. DOI: 10.1111/1759-7714.12304. View

Kris M, Natale R, Herbst R, Lynch Jr T, Prager D, Belani C . Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290(16):2149-58. DOI: 10.1001/jama.290.16.2149. View

Chen S, Tang J, Liu F, Li W, Yan T, Shangguan D . Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments. Front Immunol. 2023; 14:1094764. PMC: 10025329. DOI: 10.3389/fimmu.2023.1094764. View

Roxburgh C, McMillan D . Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014; 110(6):1409-12. PMC: 3960633. DOI: 10.1038/bjc.2014.90. View

Evans W, Morley J, Argiles J, Bales C, Baracos V, Guttridge D . Cachexia: a new definition. Clin Nutr. 2008; 27(6):793-9. DOI: 10.1016/j.clnu.2008.06.013. View

Han R, Guo H, Shi J, Wang H, Zhao S, Jia Y . Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer. Eur J Cancer. 2023; 189:112919. DOI: 10.1016/j.ejca.2023.05.007. View

10.

Soyano A, Dholaria B, Marin-Acevedo J, Diehl N, Hodge D, Luo Y . Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer. 2018; 6(1):129. PMC: 6251165. DOI: 10.1186/s40425-018-0447-2. View

11.

Rojko L, Megyesfalvi Z, Czibula E, Reiniger L, Teglasi V, Szegedi Z . Longitudinal analysis of complete blood count parameters in advanced-stage lung cancer patients. Thorac Cancer. 2020; 11(11):3193-3204. PMC: 7605999. DOI: 10.1111/1759-7714.13642. View

12.

Hwang M, Canzoniero J, Rosner S, Zhang G, White J, Belcaid Z . Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022; 10(6). PMC: 9189831. DOI: 10.1136/jitc-2022-004688. View

13.

Cupp M, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor A . Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020; 18(1):360. PMC: 7678319. DOI: 10.1186/s12916-020-01817-1. View

14.

Tiainen S, Nurmela V, Selander T, Turunen P, Pasonen-Seppanen S, Kettunen T . A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors. BMC Cancer. 2023; 23(1):1186. PMC: 10694914. DOI: 10.1186/s12885-023-11699-0. View

15.

Ding N, Pang Z, Shen H, Ni Y, Du J, Liu Q . The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort. Sci Rep. 2016; 6:34823. PMC: 5050506. DOI: 10.1038/srep34823. View

16.

Liu K, Jiang G, Fang N, Cai L, Du W, Jia J . Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer. J Int Med Res. 2020; 48(12):300060520980205. PMC: 7758664. DOI: 10.1177/0300060520980205. View

17.

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

18.

Seretis K, Sfaelos K, Boptsi E, Gaitanis G, Bassukas I . The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence beyond Malignant Melanoma. Cancers (Basel). 2024; 16(5). PMC: 10931327. DOI: 10.3390/cancers16051044. View

19.

MacDonald M, Poei D, Leyba A, Diep R, Chennapan K, Leon C . Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer. Cancer Treat Res Commun. 2023; 36:100752. PMC: 11160511. DOI: 10.1016/j.ctarc.2023.100752. View

20.

Liu H, Wu Y, Wang Z, Yao Y, Chen F, Zhang H . Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. J Thorac Dis. 2014; 5(6):783-9. PMC: 3886705. DOI: 10.3978/j.issn.2072-1439.2013.12.34. View